“…Notably, some cases of embryonal rhabdomyosarcomas may lack myogenin expression (Dias et al, 2000;Parham et al, 2012), so it is wise to include in the immunohistochemical panel also antibodies against both the Cand N-terminus of WT1 protein (clone WT 6F-H2). These latter antibodies give rise to a diffuse and strong cytoplasmic expression in rhabdomyosarcomas, regardless the subtypes (embryonal and alveolar) and the age of patients (Carpentieri et al, 2002;Sebire et al, 2005;Salvatorelli et al, 2011Salvatorelli et al, , 2015Bisceglia et al, 2011a,b;Magro et al, 2015b;Parenti et al, 2015). This unexpected finding is explained by the detection of WT1 in the cytoplasm of human developing skeletal muscle tissues (Parenti et al, 2013;Magro et al, 2015b;Musumeci et al, 2015).…”